Download this file

# pmid doi year title Hugo_Symbol
1 33297669 10.3324/haematol.2020.267294 2022 Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. TET2
2 33579790 10.1136/gutjnl-2020-322935 2022 Oncogenetic landscape of lymphomagenesis in coeliac disease. TET2
3 34494161 10.1007/s00428-021-03186-3 2022 Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin. TET2
4 35064935 10.1111/his.14619 2022 Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis. TET2
5 35255774 10.1080/15548627.2022.2048432 2022 TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss. TET2
6 35401516 10.3389/fimmu.2022.842439 2022 Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma. TET2
7 35895386 10.1111/bjd.21791 2022 Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study. TET2
8 36048893 10.1093/ajcp/aqac104 2022 Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. TET2
9 33413063 10.2174/1568009620666210106122750 2021 Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). TET2
10 33431788 10.1038/s41392-020-00437-8 2021 CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. TET2
11 33432228 10.1038/s41590-020-00827-8 2021 Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. TET2
12 33544565 10.1097/PAS.0000000000001658 2021 Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. TET2
13 33650043 10.1007/s00428-021-03071-z 2021 Clinicopathological characterization of follicular helper T-cell-derived peripheral T-cell lymphoma involving Waldeyer's ring. TET2
14 33829512 10.1111/his.14378 2021 Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma. TET2
15 33939500 10.1177/10668969211013402 2021 A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor. TET2
16 33951889 10.3324/haematol.2020.271957 2021 MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. TET2
17 34021249 10.1038/s41375-021-01289-z 2021 Thyroid MALT lymphoma: self-harm to gain potential T-cell help. TET2
18 34272731 10.1111/bjh.17708 2021 EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features. TET2
19 34447369 10.3389/fimmu.2021.671755 2021 Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. TET2
20 34449978 10.1002/dc.24861 2021 Angioimmunoblastic T-cell lymphoma diagnosed from pleural fluid by integration of morphologic, immunophenotypic, and molecular findings. TET2
21 34570179 10.1182/bloodadvances.2021004668 2021 Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. TET2
22 34590470 10.52586/4970 2021 Methylation alterations and advance of treatment in lymphoma. TET2
23 34621263 10.3389/fimmu.2021.688493 2021 Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. TET2
24 35008340 10.3390/cancers14010176 2021 Recent Advances in the Genetic of MALT Lymphomas. TET2
25 31028364 10.1038/s41379-019-0279-8 2020 Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. TET2
26 32127923 10.1177/1758835919900856 2020 Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications. TET2
27 32239385 10.1007/s11523-020-00710-4 2020 Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. TET2
28 32469082 10.1002/cncr.32866 2020 Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. TET2
29 32518946 10.1182/blood.2020005844 2020 Germline TET2 loss of function causes childhood immunodeficiency and lymphoma. TET2
30 32598477 10.1182/bloodadvances.2019001350 2020 Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. TET2
31 33160401 10.1186/s13148-020-00962-x 2020 Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. TET2
32 33376237 10.1038/s41392-020-00331-3 2020 Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. TET2
33 34667996 10.21037/aol-20-20 2020 Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. TET2
34 29629950 10.1097/PAI.0000000000000644 2019 A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification. TET2
35 30623224 10.1007/s00347-018-0840-8 2019 [New molecular pathological strategies for malignant iris tumors]. TET2
36 30632835 10.1080/10428194.2018.1516878 2019 Descriptive analysis of genetic aberrations and cell of origin in Richter transformation. TET2
37 30683910 10.1038/s41375-019-0380-5 2019 Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. TET2
38 30952970 10.1038/s41379-019-0254-4 2019 The pathological features of angioimmunoblastic T-cell lymphomas with IDH2<sup>R172</sup> mutations. TET2
39 31123138 10.1136/jclinpath-2019-205727 2019 Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis. TET2
40 31311407 10.1080/15384047.2019.1638670 2019 Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders. TET2
41 31594013 10.1055/a-0597-7606 2019 [Current standard in diagnostic and therapy of peripheral T-cell lymphoma]. TET2
42 29895903 10.1038/s41408-018-0089-0 2018 Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. TET2
43 30274972 10.1158/2159-8290.CD-18-0657 2018 TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. TET2
44 31938438 NA 2018 Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature. TET2
45 27921272 10.1007/s12185-016-2159-z 2017 BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma. TET2
46 28148900 10.18632/oncotarget.14846 2017 Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. TET2
47 28487787 10.1155/2017/5083463 2017 EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>. TET2
48 28691928 10.1172/JCI92026 2017 Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis. TET2
49 26697989 10.1016/j.critrevonc.2015.11.004 2016 Myeloproliferative neoplasms: Current molecular biology and genetics. TET2
50 27055146 10.1097/MOH.0000000000000249 2016 The many layers of epigenetic dysfunction in B-cell lymphomas. TET2
51 27203213 10.18632/oncotarget.9400 2016 Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. TET2
52 26551667 10.1038/ng.3442 2015 The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. TET2
53 24345752 10.1182/blood-2013-10-531509 2014 A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. TET2
54 24413734 10.1038/ng.2873 2014 Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. TET2
55 23298878 10.1097/MOH.0b013e32835d82fe 2013 Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. TET2